[68Ga]Ga-PSMA-11在原发前列腺癌中摄取的天间变异性:对示踪剂摄取和视觉判读的影响
肿瘤、正常组织及血池的个体内变异系数平均约10%,前列腺肿瘤重复性系数SULpeak为18%、SULmax为22%。5例视觉判读有差异但无临床相关性。结论认为摄取可重复,可用于疾病监测和疗效反应评估。
要点
- 原发前列腺癌[68Ga]Ga-PSMA-11摄取在4周内个体内变异约10%。
- 前列腺肿瘤重复性系数:SULpeak 18%,SULmax 22%。
- 视觉判读差异见于5例患者,但无临床相关性。
核心结论
- 间隔4周的重复[68Ga]Ga-PSMA-11 PET/CT显示摄取可重复,肿瘤及生理分布变异无临床相关性。
- 基于可重复的摄取,[68Ga]Ga-PSMA-11 PET/CT有望用于疾病监测和疗效反应评估。
- 超过重复性系数的摄取变化很可能反映PSMA表达的真实生物学改变。
研究设计与样本
- 患者间隔4周接受两次[68Ga]Ga-PSMA-11 PET/CT扫描,两次扫描间未开始治疗。
- 在前列腺肿瘤、正常组织和血池中测定SULmax、SULmean和SULpeak,计算各区域重复性系数。
- 所有扫描由两名核医学医师进行视觉分析。
- 试验在Trialregister.nl注册(NL8263),于2020年1月3日回顾性注册。
主要发现
- 两次扫描间[68Ga]Ga-PSMA-11摄取的个体内变异系数在前列腺肿瘤、正常组织(肝、肾、腮腺)和血池中平均约10%。
- 前列腺肿瘤重复性系数SULpeak为18%,SULmax为22%。
- 5例患者病灶摄取视觉判读有差异,但无临床相关性。
临床怎么用
- 解读[68Ga]Ga-PSMA-11 PET/CT随访时,变化超过重复性系数(如SULpeak>18%、SULmax>22%)更可能反映真实生物学改变。
- 间隔4周的重复扫描变异无临床相关性,支持将[68Ga]Ga-PSMA-11 PET/CT用于疾病监测和疗效反应评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) agents, such as [68Ga]Ga-PSMA-11, have an unprecedented accuracy in staging prostate cancer (PCa) and detecting disease recurrence. PSMA PET/CT may also be used for response monitoring by displaying molecular changes, instead of morphological changes alone. However, there are still limited data available on the variability in biodistribution and intra-prostatic uptake of PSMA targeting radiotracers. Therefore, the aim of this study was to assess the repeatability of [68Ga]Ga-PSMA-11 uptake in primary PCa patients in a 4-week interval. METHODS: Twenty-four primary PCa patients were prospectively included, who already were scheduled for [68Ga]Ga-PSMA-11 PET/CT scan on clinical indication (≥ cT3, Gleason score ≥ 7 or PSA ≥ 20 ng/mL). These patients received two [68Ga]Ga-PSMA-11 PET/CT scans with a 4-week interval. No treatment was started in between the scans. Semiquantitative measurements (SULmax, SULmean, and SULpeak) were determined in the prostate tumor, normal tissues, and blood pool. The repeatability coefficient of every region was determined. All scans were visually analyzed by two nuclear medicine physicians. RESULTS: Within-subject coefficient of variation of [68Ga]Ga-PSMA-11 uptake between the two scans was on average 10% in the prostate tumor, normal tissues (liver, kidney, parotid), and blood pool. The repeatability coefficient of the prostate tumor was 18% for SULpeak and 22% for SULmax. Lesion uptake was visually different in 5 patients, though not clinically relevant. CONCLUSION: Results of test-retest [68Ga]Ga-PSMA-11 PET/CT scans in a 4-week interval show that [68Ga]Ga-PSMA-11 uptake is repeatable, with a clinical irrelevant variation in tumor and physiological distribution. Based on the presented repeatable uptake, [68Ga]Ga-PSMA-11 PET/CT scans can potentially be used for disease surveillance and therapy response monitoring. Changes in uptake larger than the RC are therefore likely to reflect actual biological changes in PSMA expression. Trial registration NL8263 at Trialregister.nl retrospectively registered on 03-01-2020. https://www.trialregister.nl/trial/8263.
引用
- Olde Heuvel J, de Wit-van der Veen BJ, Donswijk ML, et al. Day-to-day variability of [68Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation. EJNMMI Res. 2020. PMID: 33123814. doi:10.1186/s13550-020-00708-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。